Tego Science
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Tego Science develops and supplies cell therapy products, treatments that use living cells to address conditions such as burns, foot ulcers, skin wrinkles, and tendon injuries at a biological level.
Its approved products are used in clinical and hospital settings in South Korea, and it also provides contract development, manufacturing, and quality-testing services to other cell-therapy developers. Listed on KOSDAQ, Korea's tech and small-cap board, the company holds multiple cell-therapy approvals from Korea's drug regulator and operates its own GMP-certified manufacturing facility, making contract services a growing part of its business alongside its own products.
Summary is AI-generated and may contain errors · figures from DART filings
The company holds regulatory approval for three cell-therapy products covering five indications from Korea's Ministry of Food and Drug Safety, a relatively rare position in the domestic market.
Tego Science in five facts
What does Tego Science do?
Tego Science develops and supplies cell therapy products, treatments that use living cells to address conditions such as burns, foot ulcers, skin wrinkles, and tendon injuries at a biological level.
Where is Tego Science listed and in which sector?
Tego Science (Korean name: 테고사이언스) trades under KRX code 191420 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Tego Science?
Its market capitalisation was US$41.1M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Tego Science's latest annual revenue and operating profit?
For fiscal year 2025, Tego Science reported revenue of US$4.5M, an operating loss of US$3.3M and a net loss of US$5.3M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 12.1% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersSep 22
- Report on large shareholdings (5% rule) (standard)Sep 22
- Decision to acquire shares/equity in another company (voluntary)
Tego Science disclosed an acquisition of P&P Pharm Co., Ltd., worth US$2.48M.
M&A · May 19 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)Earnings · Jan 28